Consensus Savara Inc.

Stocks

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-21 EDT			5-day change	1st Jan Change
4.670 ^USD	-1.89%		-1.89%	-22.55%

10-21	Savara Inc. Presents New Data Showing Molgramostim Inhalation Solution Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis Patients with Mild Diffusion Impairment	CI
10-12	Savara Inc. Announces New Analysis From The IMPALA Clinical Trial And Encore Presentation Of Long-Term Data On Molgramostim In Autoimmune Pulmonary Alveolar Proteinosis At CHEST 2026	CI

Evolution of the Average Target: Savara Inc.

Evolution of the Target Price: Savara Inc.

Changes in Analyst Recommendations: Savara Inc.

7ce6fb5073b7f7.rZrY1DnY3KdEegZgRhybdbg6PgB4zAJPA399HYK6Vuw.5KiypV69sZ4VQ0onDUXNAstDCjIJoloLbUc-ecX4MqiY_7WOAe227xUXdQ~bec9f427355ac7b24cbe1019011d6a92

Analysts' recommendations: Savara Inc.

10-07	JPMorgan Initiates Savara at Overweight With $12 Price Target	MT
04-24	Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating	MT
11-14	Oppenheimer Adjusts Price Target on Savara to $9 From $8, Maintains Outperform Rating	MT
25-09-08	Oppenheimer Adjusts Savara Price Target to $8 From $6, Maintains Outperform Rating	MT
25-08-15	Savara Shares Rise After Upgrade From HC Wainwright	MT
25-08-15	HC Wainwright Upgrades Savara to Buy From Neutral, $5 Price Target	MT
25-08-15	Oppenheimer Adjusts Price Target on Savara to $6 From $5, Maintains Outperform Rating	MT
25-06-02	Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating	MT
25-05-29	HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6	MT
24-12-20	Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target	MT
24-11-13	Savara Shares Fall After Evercore ISI Downgrade	MT
24-11-13	Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7	MT
24-06-27	JMP Securities Adjusts Price Target on Savara to $10 From $8, Maintains Market Outperform Rating	MT
24-06-27	Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating	MT
24-06-27	Guggenheim Adjusts Price Target on Savara to $10 From $8, Maintains Buy Rating	MT
24-06-27	HC Wainwright Raises Savara Price Target to $10 From $6, Maintains Buy Rating	MT
24-05-21	Oppenheimer Adjusts Savara Price Target to $11 From $9.50, Maintains Outperform Rating	MT
24-03-04	Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating	MT
24-02-15	JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target	MT
23-11-07	Guggenheim Starts Savara With Buy Rating, $7 Price Target	MT
23-08-14	HC Wainwright Adjusts Price Target on Savara to $6 From $3, Keeps Buy Rating	MT
23-04-03	Jefferies Downgrades Savara to Hold From Buy With $2 Price Target	MT
21-03-16	Savara : Piper Sandler Starts Savara at Overweight With $7 Price Target	MT
21-03-15	Savara : Oppenheimer Initiates Savara at Outperform With $4 Price Target	MT
20-12-15	Savara : HC Wainwright Adjusts Savara's Price Target to $3 From $6, Keeps at Buy	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SAVARA INC.					+136.74%
	WUXI APPTEC CO., LTD.					+30.22%
	ARGENX SE					+28.19%
	LONZA GROUP AG					+11.71%
	IQVIA HOLDINGS INC.					+9.41%
	BEONE MEDICINES AG					+12.94%
	REVOLUTION MEDICINES, INC.					+32.56%
	CELLTRION, INC.					+35.55%
	WUXI BIOLOGICS (CAYMAN) INC.					+21.74%
	GENMAB A/S					+5.95%
	Average					+32.50%
	Weighted average by Cap.					+22.06%